Abbvie Inc.

Abbott Laboratories Corporation

Abbvie Bahamas Limited

Abbvie Ireland Unlimited Company

Yi Gao

John K Pratt

Rolf Wagner

Todd Warren Rockway

John T Randolph

Dachun Liu

David A Betebenner

Douglas K Hutchinson

Allan C Krueger

Clarence J Maring

Pamela L Donner

David A DeGoey

Warren M Kati

Christopher E Motter

Charles A Flentge

Charles W Hutchins

Kevin R Woller

Michael D Tufano

Sachin V Patel

Tammie K Jinkerson

Mark A Matulenko

Geoff G Z Zhang

William A Carroll

Anthony Ralph Haight

Ryan G Keddy

Kathy A Sarris

Seble H Wagaw

Lissa T Nelson

Wenke Li

Mary E Bellizzi

Daniel D Caspi

Shuang Chen

Xiaochun Lou

Yaya Liu

Jonathan Miller

Eric Allen Schmitt

Yi Shi

Ping Gao

Thomas Kessler

Rodger F Henry

David M Barnes

Kent D Stewart

Kenton L Longenecker

Bernd Liepold

Geoff G Zhang

Jean-Christophe C Califano

Joerg Rosenberg

Russell Drew Cink

Kevin R Engh

Dennis Y Lee

Brian J Kotecki

Nancy E Sever

Jean C Califano

John B Morris

Mirko Pauli

Rajeev Gokhale

Carl M Knable

Mark Costello

Jianwei Wu

Drazen Kostelac

Peter Hoelig

Anna Moosmann

Fatih Durak

Karin Rosenblatt

John E Hengeveld

Ulrich Westedt

Justin S Lafountaine

Ping Tong

David A Degoey

Rudolf Schroeder

Ute Lander

Peter Hölig

Harald Hach

Yanxia Li

Tzuchi R Ju

Bryan K Erickson

Joseph B Paterson, Jr

Adivaraha Jayasankar

Donghua Zhu

Thomas Mueller

Marius Naris

Colleen Garrett

Simon Kullmann

Gerd Woehrle

Regina Reul

Tanja Heitermann

Renato Koenig

Madlen Thiel

Tina Jung

Constanze Obermiller

Brent D Sinclair

Lloyd Dias

Charles A Flengte

Michelle A Long

Susan George

Katrin Schneider

Michael Simon

Samuel Kyeremateng

Benedikt Steitz

Katharina Asmus

The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Solid pharmaceutical compositions for treating HCV

The present disclosure relates to pharmaceutical compositions of pyrimidinedione derivative compounds and methods of preparing and uses thereof. The disclosure also relates to methods of enhancing bioavailability of pyrimidinedione derivative compounds in pharmaceutical compositions administered to a subject and methods of reducing the amount of a pyrimidinedione derivative compound in a pharmaceutical composition while achieving the same bioavailability in a subject.

Formulations of pyrimidinedione derivative compounds

The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.

Solid antiviral dosage forms

Compounds effective in inhibiting replication of Hepatitis C virus ('HCV') are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Anti-infective agents and uses thereof

The present invention features solid compositions comprising a selected HCV inhibitor in an amorphous form. In one embodiment, the selected HCV inhibitor is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.

Solid compositions

The present invention features solid compositions comprising Compound I, Ior I, or a pharmaceutically acceptable salt thereof, in an amorphous form. In one embodiment, Compound I, Ior I, or a pharmaceutically acceptable salt thereof, is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.

Growing community of inventors

Vernon Hills, IL, United States of America

Yi Gao